Cargando…

T35. A PHASE 3, MULTICENTER STUDY TO ASSESS THE 1-YEAR SAFETY AND TOLERABILITY OF A COMBINATION OF OLANZAPINE AND SAMIDORPHAN IN PATIENTS WITH SCHIZOPHRENIA: RESULTS FROM THE ENLIGHTEN-2-EXTENSION

Abstract not included.

Detalles Bibliográficos
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2020
Materias:	Poster Session III
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7233886/ http://dx.doi.org/10.1093/schbul/sbaa029.595

Ejemplares similares

Insulin and glucose metabolism with olanzapine and a combination of olanzapine and samidorphan: exploratory phase 1 results in healthy volunteers
por: Toledo, Frederico G. S., et al.
Publicado: (2021)

T41. SAFETY PROFILE OF ADJUNCTIVE PIMAVANSERIN IN THE ENHANCE STUDY, A PHASE 3 TRIAL FOR THE POTENTIAL TREATMENT OF SCHIZOPHRENIA IN PATIENTS WITH AN INADEQUATE RESPONSE TO ANTIPSYCHOTIC TREATMENT
por: Bugarski-Kirola, Dragana, et al.
Publicado: (2020)

Effects of Combined Therapy of Olanzapine and Samidorphan on Safety and Metabolic Parameters in Schizophrenia Patients: A Meta-Analysis
por: Peng, Zhenlei, et al.
Publicado: (2023)

T205. LUMATEPERONE IN THE TREATMENT OF SCHIZOPHRENIA: EVALUATION OF EXTRAPYRAMIDAL AND MOTOR SYMPTOMS IN 4 LATE-PHASE CLINICAL TRIALS
por: Durgam, Suresh, et al.
Publicado: (2020)

Population Pharmacokinetics of Olanzapine and Samidorphan When Administered in Combination in Healthy Subjects and Patients With Schizophrenia
por: Sun, Lei, et al.
Publicado: (2021)

Combining samidorphan with olanzapine to mitigate weight gain as a side effect in schizophrenia treatment
por: Grywińska, Weronika B., et al.
Publicado: (2023)

The Facts and Fiction of Olanzapine-Samidorphan Fixed Dose Combination
por: Das, Nileswar, et al.
Publicado: (2022)

T185. OLIGOPEPTIDASES IN SCHIZOPHRENIA
Publicado: (2020)

Samidorphan/olanzapine combination therapy for schizophrenia: Efficacy, tolerance and adverse outcomes of regimen, evidence-based review of clinical trials
por: Rehan, Syeda Tayyaba, et al.
Publicado: (2022)

T219. REAL LIFE FUNCTIONING IN 22Q11 DELETION SYNDROME (DS) IN COMPARISON TO SCHIZOPHRENIA SUBJECTS: STUDY ON PSYCHOSES VULNERABILITY FACTORS. DATA FROM THE MULTICENTER STUDY OF THE ITALIAN NETWORK FOR RESEARCH ON PSYCHOSES
por: Carlone, Luca, et al.
Publicado: (2020)

T59. ACOUSTIC SPEECH MARKERS FOR SCHIZOPHRENIA
por: de Boer, Janna, et al.
Publicado: (2020)

T186. IMPACT OF A STRUCTURED VALIDATED FAMILY PSYCHOEDUCATIONAL PROGRAM (PROFAMILLE) ON MENTAL HEALTH CARE OF PEOPLE WITH SCHIZOPHRENIA SPECTRUM DISORDERS: PRELIMINARY RESULTS
por: Bralet, Marie-Cécile, et al.
Publicado: (2020)

T2. ADVERSE CHILDHOOD EXPERIENCES IN PEOPLE WITH SCHIZOPHRENIA
por: Klaunig, Mallory, et al.
Publicado: (2020)

T90. QUANTIFYING THE CORE DEFICIT IN CLASSICAL SCHIZOPHRENIA
por: Rathnaiah, Mohanbabu, et al.
Publicado: (2020)

T197. TREATMENT STRATEGIES FOR ULTRA-RESISTANT SCHIZOPHRENIAS
por: Vasiliu, Octavian
Publicado: (2020)

T11. CORONARY ARTERY CALCIFICATION IN PEOPLE WITH SCHIZOPHRENIA
por: Trab, Trine, et al.
Publicado: (2020)

T42. HIGH ADHERENCE TO CURRENT ANTIPSYCHOTIC AND ADJUNCTIVE PIMAVANSERIN IN THE ENHANCE STUDY, A PHASE 3 TRIAL TO EVALUATE THE TREATMENT OF SCHIZOPHRENIA IN PATIENTS WITH AN INADEQUATE RESPONSE TO ANTIPSYCHOTIC TREATMENT
por: Abbs, Brandon, et al.
Publicado: (2020)

T19. GLUTAMATE AND RESPONSE TO CLOZAPINE IN TREATMENT RESISTANT SCHIZOPHRENIA
por: Egerton, Alice, et al.
Publicado: (2020)

T98. CHARACTERIZING THE CLINICAL COURSE IN SCHIZOPHRENIA WITH DIGITAL PHENOTYPING
por: Torous, John, et al.
Publicado: (2020)

T8. ANTIPSYCHOTIC TREATMENT AND EYE MOVEMENT ABNORMALITIES IN SCHIZOPHRENIA
por: Takahashi, Junichi, et al.
Publicado: (2020)

T77. ASSOCIATION BETWEEN INTRACELLULAR INFECTIOUS AGENTS AND SCHIZOPHRENIA
por: Kwon, Young-Joon, et al.
Publicado: (2020)

T132. RETINAL GANGLION CELLS DYSFUNCTIONS IN SCHIZOPHRENIA PATIENTS
por: Bernadin, Florent, et al.
Publicado: (2020)

T47. GUANFACINE AUGMENTATION OF ATTENTIONAL FUNCTIONING IN THE SCHIZOPHRENIA SPECTRUM
Publicado: (2020)

T110. CLINICAL CHARACTERISTICS OF FORMAL THOUGHT DISORDER IN SCHIZOPHRENIA
por: Lee, Euijin, et al.
Publicado: (2020)

T228. SOCIAL REWARD REACTIVITY AND SENSITIVITY IN SCHIZOPHRENIA SPECTRUM CONDITIONS
por: Aldridge-Waddon, Luke, et al.
Publicado: (2020)

T16. SCHIZOPHRENIA SPECTRUM DISORDER: DEPRESSION TRAJECTORIES AND IMMUNE MARKERS
por: Hoprekstad, Gunnhild, et al.
Publicado: (2020)

T13. CORNEAL CONFOCAL MICROSCOPY DETECTS NEURAL CHANGES IN SCHIZOPHRENIA
por: Woodruff, Peter, et al.
Publicado: (2020)

T83. SUBSTANCE-INDUCED PSYCHOSIS LINKED TO BOTH INFECTIONS AND SCHIZOPHRENIA
por: Hjorthøj, Carsten, et al.
Publicado: (2020)

T176. INSIGHTS INTO THE ROLE OF ORAL AND GUT MICROBIOME IN THE PATHOGENESIS OF SCHIZOPHRENIA
por: Ghorbani, Mahin, et al.
Publicado: (2020)

T45. THE EFFICACY AND HETEROGENEITY OF ANTIPSYCHOTIC RESPONSE IN SCHIZOPHRENIA: A META-ANALYSIS
por: McCutcheon, Rob, et al.
Publicado: (2020)

T93. RESHAPING THE DIAGNOSTIC BORDERS OF SCHIZOPHRENIA: THE LOOK OF HISTORY OF PSYCHIATRIC PRACTICES
por: Clauss, Julie, et al.
Publicado: (2020)

T99. HARNESSING DIGITAL TECHNOLOGIES TO ASSESS AND TREAT COGNITIVE SYMPTOMS IN SCHIZOPHRENIA
por: Shvetz, Cecelia, et al.
Publicado: (2020)

T15. MISMATCH NEGATIVITY INDICES AS A PROGNOSTIC FACTOR FOR REMISSION IN SCHIZOPHRENIA
por: Shim, Se-Hoon, et al.
Publicado: (2020)

T62. A COMPUTATIONAL ANALYSIS OF MOTIVATIONAL DEFICITS IN SCHIZOPHRENIA SPECTRUM DISORDERS
por: Waltz, James, et al.
Publicado: (2020)

T222. IMPAIRED COST-BENEFIT COMPUTATION IN SOCIAL CONTEXT IN PATIENTS WITH SCHIZOPHRENIA
por: Yan, Chao, et al.
Publicado: (2020)

T73. COGNITIVE CLUSTERING IN SCHIZOPHRENIA SPECTRUM DISORDER AND THE ASSOCIATION WITH BRAIN VOLUME
por: Oomen, Priscilla, et al.
Publicado: (2020)

T51. VERBAL MEMORY TRAJECTORIES IN CHRONIC INDIVIDUALS WITH SCHIZOPHRENIA ALONG 6 YEARS
por: Martins, Dayane, et al.
Publicado: (2020)

T143. RESTING STATE FMRI BASED MULTILAYER NETWORK CONFIGURATION IN PATIENTS WITH SCHIZOPHRENIA
por: Gifford, George, et al.
Publicado: (2020)

T216. VARIATION IN SIDE EFFECTS TO ANTIPSYCHOTIC TREATMENT ACROSS SCHIZOPHRENIA SPECTRUM DISORDERS
por: Susanne Neumeier, Maria, et al.
Publicado: (2020)

T229. CAREGIVER BURDEN IN TREATMENT RESISTANT VERSUS NON-TREATMENT RESISTANT SCHIZOPHRENIA
por: Di Sarno, Elaine, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_je8i4avagpftjbb5fbg5fj6lmd